Direct costs of ankylosing spondylitis and its determinants: An analysis among three European countries

Annals of the Rheumatic Diseases

Volumn 62, Issue 8, 2003, Pages 732-740

  Boonen, A ^a   van der Heijde, D ^a   Landewe R ^a   Guillemin, F ^b   Rutten Van Molken M ^c   Dougados, M ^d   Mielants, H ^e   de Vlam, K ^e   van der Tempel, H ^f   Boesen, S ^g   Spoorenberg, A ^a   Schouten, H ^g   van der Linden, Sj ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f Sittard Geleen Heerlen   (Netherlands)

^g MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIRHEUMATIC AGENT; CORTICOSTEROID; GASTROINTESTINAL AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; BELGIUM; DISEASE ACTIVITY; DRUG COST; EUROPE; FEMALE; FRANCE; GASTROINTESTINAL DISEASE; GENERAL PRACTICE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; NETHERLANDS; PHYSIOTHERAPIST; PRIORITY JOURNAL; RESOURCE ALLOCATION;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; BELGIUM; COST OF ILLNESS; DIRECT SERVICE COSTS; DRUG COSTS; FEMALE; FOLLOW-UP STUDIES; FRANCE; HEALTH EXPENDITURES; HEALTH SERVICES; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PROSPECTIVE STUDIES; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; STATISTICS;

EID: 0038675213     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.62.8.732     Document Type: Article

References (50)

1. Koopmanschap MA. Cost-of-illness studies. Useful for health policy? Pharmacoeconomics 1998;14:143-8.
2. Hodgson TA. Costs of illness in cost-effectiveness analysis. A review of the methodology. Pharmacoeconomics 1994;6:536-52.
3. Byford S, Torgerson DJ, Raftery J. Economic note: cost of illness studies. BMJ 2000;320:1335.
4. Bloom BS, Bruno DJ, Maman DY, Jayadevappa R. Usefulness of US cost-of-illness studies in healthcare decision making. Pharmacoeconomics 2001;19:207-13.
5. Rice DP. Cost of illness studies: what is good about them? Inj Prev 2000;6:177-9.
6. Sailly JC, Lebrun T. [Socioeconomic and social consequences of rheumatic pelvispondylitis]. Rev Epidemiol Sante Publique 1982;30:305-24.
7. Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 2002;46:223-31.
8. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41:58-67.
9. van der Linden SM, Valkenburg HA, de Jongh BM, Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 1984;27:241-9.
10. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
11. Dalyan M, Guner A, Tuncer S, Bilgic A, Arasil T. Disability in ankylosing spondylitis. Disabil Rehabil 1999;21:74-9.
12. Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 1997;36:766-71.
13. Makisara GL, Makisara P. Prognosis of functional capacity and work capaciy in rheumatoid arthritis. Clin Rheumatol 1982;1:117-25.
14. Boonen A, van der Heijde R, Spoorenberg A, Boesen S, Guillemin F, Dougados M, et al. Direct costs of ankylosing spondylitis and its determinants. An analysis among three European countries [abstract]. Ann Rheum Dis 2002;61:429-37.
15. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
16. Lubeck DP, Spitz PW, Fries JF, Wolfe F, Mitchell DM, Roth SH. A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum 1986;29:488-93.
17. Verhoeven AC, Bibo JC, Boers M, Engel GL, van der Linden S. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. Combinatietherapie Bij Reumatoide Artritis. Br J Rheumatol 1998;37:1102-9.
18. Goossens ME, Rutten-van Molken MP, Vlaeyen JW, van der Linden SM. The cost diary: a method to measure direct and indirect costs in cost-effectiveness research. J Clin Epidemiol 2000;53:688-95.
19. Scott DL, van Riel PL, van der Heijde D, Benke AS. Assessing disease activity in rheumatoid arthritis. EULAR Standing Committee on Clinical Trials, 1993.
20. Rutten- van Molken MPMH, Van Doorslaer EKA. [Multinational cost-effectivity analyses]. In: [From costs to effects. A guideline for evaluations in healthcare]. Maarssen: Elsevier gezondheidszorg, 2000:31-149.
21. Oostenbrink J, Koopmanschap M, Rutten F. [Guideline for cost-evaluations. Methods and cost-estimates for economic evaluations in healthcare]. Amstelveen: College voor zorgverzekeraars, 2000.
22. Evers S, van Merode F, Paulus A. [Direct costs of chronic benign pain]. Maastricht: Department af Health Organisation, Policy and Economics, University Maastricht, 1999.
23. Anonymous. [Taxe WTG; Pricelist Law Tariffs Drugs]. The Hague: Royal Dutch Society for Pharmacology, 1998.
24. Anonymous. [Taxe non-WTG, OTC; Pricelist extra-Law Tariffs Drugs, over-the-counter and sales by hand]. The Hague: Royal Dutch Society for Pharmacology, 1998.
25. Anonymous. [Tariffs medical specialists, medical prestations, hospitalisations]. The Hague, The Netherlands: Central Organ Tariffs in Healthcare, 1998.
26. Anonymous. [Nomenclature of medical presentations]. Brussels: National Institute of Illness and Invalidity, 1998.
27. Anonymous. [Reimbursement rates sickness and invalidity insurance]. Brussels: National Institute of Illness and Invalidity, 1998.
28. Anonymous. [Nomenclature of medical presentations]. Paris: Caisse Nationale d'Assurance Maladie, 1998.
29. Anonymous. [Vidal dictionary of drugs]. 74 ed. Paris: Editions du Vidal, 1998.
30. Anonymous. [Pricelist pharmaceutical specialties]. Brussels: National Institute of Illness and Invalidity, 1998.
31. Efron B, Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci 1986;1:54-77.
32. Boonen A, Chorus A, Miedema H, van der Heijde D, van der Tempel H, van der Linden S. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 2001;60:353-8.
33. Miedema HS, Van der Linden SM, Rasker JJ, Valkenburg HA. National database of patients visiting rheumatologists in the Netherlands: the standard diagnosis register of rheumatic diseases. A report and preliminary analysis. Br J Rheumatol 1998;37:555-61.
34. Anonymous. Eurostat European official statistics, a guide to databases. Luxembourg: Office for Official Publications of the European Communities, 1997.
35. OECD. Health Data File [CD-ROM], Paris: OECD, 1999.
36. Yeliln E, Meenan R, Nevitt M, Epstein W. Work disability in rheumatoid arthritis: effects of disease, social, and work factors. Ann Intern Med 1980;93:551-6.
37. Yelin EH, Henke CJ, Kramer JS, Nevitt MC, Shearn M, Epstein WV. A comparison of the treatment of rheumatoid arthritis in health maintenance organizations and fee-for-service practices. N Engl J Med 1985;312:962-7.
38. Yelin E, Herrndorf A, Truin L, Sonneborn D. A national study of medical care expenditures for musculoskeletal conditions. The impact of health insurance and managed care. Arthritis Rheum 2001;44:1160-9.
39. Esdaile JM, Sampalis JS, Lacaille D, Danoff D. The relationship of socioeconomic status to subsequent health status in systemic lupus erythematosus. Arthritis Rheum 1988;31:423-7.
40. Karlson EW, Daltroy LH, Lew RA, Wright EA, Partridge AJ, Fossel AH, et al. The relationship of socioeconomic status, race, and modifiable risk factors to outcomes in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:47-56.
41. Sutcliff N, Clarke A, Gordon C, Farewell V, Isenberg D. The association of socioeconomic status, race, psycho-social factors and outcome in patients with systemic lupus erythematosus. Rheumatology (Oxford) 1999;38:1130-7.
42. Rivest C, Lew RA, Welsing PM, Sangha O, Wright EA, Roberts WN, et al. Association between clinical factors, socioeconomic status, and organ damage in recent onset systemic lupus erythematosus. J Rheumatol 2000;27:680-4.
43. Boonen A, van der Heijde D, Landewe R, Spoorenberg A, Schouten H, Rutten van Molken M, et al. Work status ancl productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 2002;61:429-37.
44. Koopmanschap MA, Rutten FFH. A practical guide for calculating the indirect costs of disease. Pharmacoeconomics 1996;10:460-6.
45. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2000;39:26-33.
46. Newhall-Perry K, Law NJ, Ramos B, Sterz M, Wong WK, Bulpitt KJ, et al. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. J Rheumatol 2000;27:1156-63.
47. Oostenbrink JB, Rutten van Molken MP, Sluyter Opdenoordt TS. Resource use and costs of patients with glaucoma or ocular hypertension: a one-year study based on retrospective chart review in the Netherlands. J Glaucoma 2001;10:184-91.
48. Ruof J, Merkesdal S, Huelsemann JL, Schoeffski O, Maetzel A, Mau W, et al. Cost assessment instrument in rheumatology: evaluation of applied instrument characteristics. J Rheumatol 2001;28:662-5.
49. Clarke A, Petri MA, Manzi S, Isenberg DA, Gordon C, Senecal J-L, et al. An international perspective on the well being and health care costs for patients with systemic lupus erythematosus. J Rheumatol 1999;26:1500-11.
50. Sutcliff N, Clarke A, Levinton C, Frost C, Gordon C, Isenberg C. Associates of health status in patients with systemic lupus erythematosus. J Rheumatol 1999;26:2352-6.